P4, N=70, Active, not recruiting, Medical University of Graz | Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Oct 2024 --> Mar 2025

P1, N=80, Not yet recruiting, Department of Ophthalmology and Visual Sciences, CUHK; Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong

P=N/A, N=850, Not yet recruiting, Hoffmann-La Roche

Knockdown of USP9X attenuated the regulatory effects of MSC-sEV on Ang-2 expression, LSEC angiogenesis, and the progression of MASH. In conclusion, our findings indicate that USP9X delivered via MSC-sEV can suppress LSEC angiogenesis and alleviate MASH-induced liver fibrosis through the IκBα/NF-κB/Ang-2 signaling pathway.

P1, N=252, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed

P3, N=1036, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed

After development of acquired resistance, biopsy of one patient's KRAS wild-type, ERBB2 amplified tumor showed a substantial decline in tumor-associated T cells and an increase in immunosuppressive intratumoral macrophages. Future studies are needed to carefully assess whether clinicogenomic features, such as lack of liver metastases, ERBB2 amplification, and left-sided tumors, can predict increased sensitivity to PD1 immunotherapy combinations.

Furthermore, therapeutic peptides successfully inhibited ESM1's induction of the aforementioned signals and motility of GC cells. ESM1's oncogenic role in GC involves activating the EGFR/HER3-Akt/ANGPT2 pathway, presenting a potential therapeutic target for GC.

However, the constructed biosensor is characterized by its ease and speed of measurement, and the method does not require special preparation of samples. SPRi biosensors can be used as a sensitive and highly selective method for determining potential blood biomarkers, which in the future may become part of the routine diagnosis of cancers.

P2/3, N=30, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

P3, N=600, Recruiting, Jaeb Center for Health Research | Trial completion date: Nov 2028 --> Dec 2029 | Trial primary completion date: Nov 2026 --> Dec 2029

P4, N=100, Enrolling by invitation, University of Colorado, Denver | Not yet recruiting --> Enrolling by invitation

P1, N=48, Active, not recruiting, Boehringer Ingelheim | Trial primary completion date: Nov 2024 --> Jul 2024

P4, N=446, Recruiting, McMaster University | Trial primary completion date: Apr 2024 --> Aug 2026

P=N/A, N=1000, Recruiting, Hoffmann-La Roche

Increased levels of angiopoietin-2 and tumor necrosis factor α were observed. Early detection of these markers can assist in the clinical diagnosis and guide the appropriate use of antibiotics.

P4, N=100, Not yet recruiting, University of Colorado, Denver | Initiation date: Mar 2024 --> Aug 2024

Our studies show that the NRASQ61R mutation in endothelial cells induces Ang-2 expression in vitro and in vivo. In cultured human endothelial cells, NRASQ61R drives elevated Ang-2 through MAP kinase and mTOR-dependent signaling pathways.

In women, angiopoietin-2 was associated with PWV (β = 0.18). The selected GFs were closely related to atherosclerosis in patients with RA and are potential predictors of CV disease in patients with RA.

P1, N=48, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Nov 2024

P2, N=150, Active, not recruiting, Greater Houston Retina Research | Recruiting --> Active, not recruiting

P1, N=45, Recruiting, Boehringer Ingelheim | Active, not recruiting --> Recruiting | Trial primary completion date: Aug 2024 --> Apr 2025

P1, N=47, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting

P1, N=60, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Feb 2024 --> Feb 2025

P3, N=280, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting

P=N/A, N=100, Not yet recruiting, Nantes University Hospital

P=N/A, N=13, Completed, Rigshospitalet, Denmark

P3, N=600, Recruiting, Jaeb Center for Health Research | Not yet recruiting --> Recruiting

Data suggest a causal link between cytokines (risk factor), lung damage (mediator), and COVID-19 outcomes.

Inhibitors targeting ANG-2 (Trebananib) and the VEGF (Bevacizumab) effectively blocked the migration ability of spheroids that had been stimulated with rh-ANG-2 and rh-VEGF. Overall, our findings highlight the critical role played by ANG-2 and the VEGF in enhancing the ability of HCC- and iCCA-derived spheroids to migrate and invade, which are key processes in cancer progression.

P4, N=70, Active, not recruiting, Medical University of Graz | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2024 --> Oct 2024

At the EOT24W, serum Ang-2 level predicts the likelihood of developing HCC following SVR to DAA therapy.

P4, N=100, Not yet recruiting, University of Colorado, Denver

P4, N=446, Recruiting, McMaster University

P3, N=600, Recruiting, Jaeb Center for Health Research | Not yet recruiting --> Recruiting

P3, N=280, Not yet recruiting, Hoffmann-La Roche

The Ang/Tie2 axis inhibitor trebananib combined with standard neoadjuvant therapy increased estimated pCR rates across HR-negative and MP2 subtypes, with probabilities of superiority >90%. Further study of Ang/Tie2 receptor axis inhibitors in validated, biomarker-predicted sensitive subtypes is warranted.

P=N/A, N=46, Completed, Rigshospitalet, Denmark | Active, not recruiting --> Completed

P2, N=99, Completed, Hoffmann-La Roche | Phase classification: P2b --> P2

P1, N=45, Recruiting, Boehringer Ingelheim | N=150 --> 45

P1/2, N=43, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed

P=N/A, N=58, Active, not recruiting, Rigshospitalet, Denmark